Back | Next |
home / stock / nrbo / nrbo message board
Subject | By | Source | When |
---|---|---|---|
$NRBO best news of the day | tw0122 | investorshub | 01/29/2024 3:32:25 AM |
$NRBO The now | reena969 | investorshub | 01/29/2024 2:03:40 AM |
news out | glens0 | investorshub | 01/28/2024 11:30:17 PM |
$NRBO Price gaining last up | SmellMyFinger | investorshub | 01/28/2024 9:09:28 PM |
Price gaining | PENNY DIPZ | investorshub | 01/28/2024 7:33:21 PM |
should we be shorting? | subslover | investorshub | 01/28/2024 12:55:32 PM |
Do we have a winner?Turn around time? | BesaoT35 | investorshub | 01/28/2024 10:32:56 AM |
Price now | BesaoT35 | investorshub | 01/28/2024 8:55:47 AM |
$NRBO The now | BJ-Trader | investorshub | 01/28/2024 6:51:36 AM |
The now | db101 | investorshub | 01/28/2024 4:17:38 AM |
The trading | SmellMyFinger | investorshub | 01/28/2024 3:17:42 AM |
$NRBO Do we have a winner?Turn around time? | gr8investment | investorshub | 01/28/2024 2:27:06 AM |
must see | reena969 | investorshub | 01/28/2024 2:10:20 AM |
$NRBO MomentumIts trading last up | tw0122 | investorshub | 01/28/2024 1:51:20 AM |
$NRBO Do we have a winner?Turn around time? | BesaoT35 | investorshub | 01/27/2024 11:27:38 PM |
The gaining | BesaoT35 | investorshub | 01/27/2024 10:31:35 PM |
great news | SmellMyFinger | investorshub | 01/27/2024 6:06:44 PM |
Have a look at this | 81vette | investorshub | 01/27/2024 5:34:01 PM |
$NRBO short squeeze all day | tw0122 | investorshub | 01/27/2024 2:09:17 PM |
$NRBO MomentumIts trading | FROZENFLAME | investorshub | 01/27/2024 11:20:15 AM |
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third Quarter ...
NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June PR Newswire CAMBRIDGE, Mass. , April 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO...
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the ...